By Michael Dabaie


Teva Pharmaceuticals Industries Ltd. and MedinCell on Thursday said results were positive for Phase 3 clinical trial of TV-46000/mdc-IRM as a treatment for patients with schizophrenia.

Trial enrollment was open to patients 13-65 years of age. In the RISE study, patients treated with the investigational subcutaneous risperidone injection either monthly or once every two months experienced a statistically significant delay in time to relapse versus placebo, the study's primary objective.

No new safety signals have been identified that are inconsistent with the known safety profile of other risperidone formulations.

Teva will continue to lead the clinical development and regulatory process and be responsible for commercialization of this candidate treatment, with MedinCell eligible for development milestones, royalties on net sales and future commercial milestones.

Teva shares were up 0.7%, to $11.17, premarket.


Write to Michael Dabaie at


(END) Dow Jones Newswires

January 07, 2021 08:57 ET (13:57 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.